gptkbp:instance_of
|
gptkb:sneaker
|
gptkbp:bfsLayer
|
5
|
gptkbp:bfsParent
|
gptkb:Latisse
|
gptkbp:approves
|
gptkb:FDA
|
gptkbp:average_temperature
|
room temperature
|
gptkbp:brand
|
gptkb:Lumigan
|
gptkbp:category
|
Category C
|
gptkbp:class
|
prostaglandin analogs
|
gptkbp:clinical_trial
|
Phase III trials
ophthalmology
|
gptkbp:community_service
|
safety not established
|
gptkbp:contraindication
|
hypersensitivity to bimatoprost
|
gptkbp:dosage_form
|
gptkb:software_framework
|
gptkbp:duration
|
24 hours
|
gptkbp:effective_date
|
gptkb:2001
|
gptkbp:excretion
|
urine
|
gptkbp:formulation
|
gptkb:sneaker
newer formulations available
|
https://www.w3.org/2000/01/rdf-schema#label
|
Lumigan
|
gptkbp:indication
|
gptkb:ocular_hypertension
|
gptkbp:ingredients
|
gptkb:bimatoprost
|
gptkbp:interacts_with
|
other eye medications
systemic medications
|
gptkbp:is_available_on
|
generic version
|
gptkbp:is_used_for
|
treatment of glaucoma
|
gptkbp:manager
|
topical
|
gptkbp:manufacturer
|
gptkb:Allergan
|
gptkbp:marketed_as
|
gptkb:legislation
gptkb:United_States
gptkb:Native_American_tribe
|
gptkbp:metabolism
|
liver
|
gptkbp:packaging
|
gptkb:beer
|
gptkbp:population
|
instructions for use
|
gptkbp:premiered_on
|
4 hours
|
gptkbp:price
|
varies by pharmacy
|
gptkbp:provides_information_on
|
gptkb:American_Academy_of_Ophthalmology
gptkb:European_Glaucoma_Society
follow prescribing information
|
gptkbp:reproduction
|
caution advised
|
gptkbp:requires
|
prescription only
|
gptkbp:research_focus
|
patient quality of life
cost-effectiveness
long-term effects
comparative effectiveness
|
gptkbp:safety_features
|
generally well tolerated
|
gptkbp:side_effect
|
dry eyes
eye irritation
hyperemia
periorbital skin pigmentation
changes in eyelash growth
eyelash darkening
iris pigmentation
|
gptkbp:type_of_care
|
important for efficacy
|